Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development

Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development

Evommune (NYSE:EVMN) has licensed global development rights outside Greater China to EVO570, an experimental oral drug for inflammatory diseases, in a deal with Hinova Pharmaceuticals that includes $20 million in cash and $10 million in warrants issued at signing. The company plans to test EVO570 f

Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript

Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases November 5, 2026 8:30 AM ESTCompany ParticipantsLuis Peña - Founder,...

Evommune licenses Hinova autoimmune drug in up to $1.1 billion deal - Regional Media News

Nov 4 (Reuters) - Evommune said on Wednesday it had licensed rights to an experimental autoimmune disease treatment from China's Hinova Pharmaceuticals in a deal worth up to about $1.1 billion in milestone payments. Here are some details: • Under the agreement, Evommune will gain [...]

Evommune licenses Hinova autoimmune drug in up to $1.1 billion deal

Nov 4 (Reuters) - Evommune said on Wednesday it had licensed rights to an experimental autoimmune disease treatment from ​China's Hinova Pharmaceuticals in a deal ‌worth up to about $1.1 billion in milestone payments. Here are some details: • Under the...

Caldera, Evommune sign China licensing deals for autoimmune drugs

Caldera Therapeutics is going back to its existing partner Qyuns Therapeutics for a IL-17xTL1A bispecific antibody, while Evommune chose Hinova Pharmaceuticals for an oral molecular glue degrader.

Evommune signs $1.1bn licence deal with Hinova for EVO570

Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares. Hinova is eligible to receive the remainder of the deal The post Evommune signs $1.1bn licence deal with Hinova for EVO570 appeared first on Pharmaceutical Business review.